TiGenix : national reimbursement in the Netherlands obtained for breakthrough cartilage therapy ChondroCelect®
(Thomson Reuters ONE) -
Regulated information
June 8, 2012
TiGenix obtains national reimbursement in the Netherlands for breakthrough
cartilage therapy ChondroCelect(®)
Leuven (BELGIUM) - June 8, 2012 - TiGenix (NYSE Euronext: TIG) announced today
that its innovative cartilage repair therapy ChondroCelect(®) has obtained
national reimbursement in the Netherlands. The Dutch National Health Authority
(NZa) has formally announced that ChondroCelect(®) is to receive national
reimbursement retroactively per January 1, 2012. Previously ChondroCelect(®) was
made available in the Netherlands under a risk-sharing scheme.
"We are delighted with the decision of the NZa to reimburse ChondroCelect(®),
and look forward to working with Dutch orthopedic centers of excellence and
health insurers to routinely make this breakthrough therapy available to the
right patients in the Netherlands," said Eduardo Bravo, CEO of TiGenix. "Dutch
clinicians and scientists have been instrumental in ChondroCelect's development
and four Cartilage Expert Centers in the Netherlands have already gained
extensive experience with the procedure. After having obtained national
reimbursement in Belgium last year, this constitutes another major step in
improving patient access to this innovative therapy. We remain optimistic that
we can obtain national reimbursement in other European countries later this
year."
For more information:
Eduardo Bravo
Chief Executive Officer
eduardo.bravo(at)tigenix.com
Claudia D'Augusta
Chief Financial Officer
claudia.daugusta(at)tigenix.com
Hans Herklots
Director Investor & Media Relations
hans.herklots(at)tigenix.com
+32 16 39 60 97
About TiGenix
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy
company with a marketed product for cartilage repair, ChondroCelect(®), and a
strong pipeline with clinical stage allogeneic adult stem cell programs for the
treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen
(the Netherlands). For more information please visit www.tigenix.com.
About ChondroCelect
ChondroCelect is the first and currently only cell therapy that has been granted
market authorisation by the European Union in accordance with the Advanced
Therapy Medicinal Product regulation EC1394/2007. For more information,
including the European Public Assessment Report (EPAR), prescribing information,
and the Summary of Product Characteristics (SPC) please visit the European
Medicines Agency (EMA) website at www.ema.europa.eu.
Forward-looking information
This document may contain forward-looking statements and estimates with respect
to the anticipated future performance of TiGenix and the market in which it
operates. Certain of these statements, forecasts and estimates can be recognised
by the use of words such as, without limitation, "believes", "anticipates",
"expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties and other
factors, which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix' control. Therefore, actual results, the financial condition,
performance or achievements of TiGenix, or industry results, may turn out to be
materially different from any future results, performance or achievements
expressed or implied by such statements, forecasts and estimates. Given these
uncertainties, no representations are made as to the accuracy or fairness of
such forward-looking statements, forecasts and estimates. Furthermore, forward-
looking statements, forecasts and estimates only speak as of the date of the
publication of this document. TiGenix disclaims any obligation to update any
such forward-looking statement, forecast or estimates to reflect any change in
TiGenix' expectations with regard thereto, or any change in events, conditions
or circumstances on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via Thomson Reuters ONE
[HUG#1617505]
Unternehmensinformation / Kurzprofil:
Datum: 08.06.2012 - 07:01 Uhr
Sprache: Deutsch
News-ID 154503
Anzahl Zeichen: 5690
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 276 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix : national reimbursement in the Netherlands obtained for breakthrough cartilage therapy ChondroCelect®"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
